Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth ...

Labcorp Holdings Inc. LH, or Labcorp, is positioning itself for sustained growth with a series of strategic acquisitions and partnerships. With a growing emphasis on cell and gene therapy, the company ...

Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39. Sales increased 9.8% year-over-year to ...

Laboratory Corp (NYSE: LH) on Thursday reported second-quarter 2025 adjusted earnings per share of $4.35, up from $3.94 a year ago, beating the consensus of $4.17. Sales increased 9.5% year-over-year ...

Citi upgraded Charles River Laboratories (NYSE:CRL) and LabCorp (NYSE:LH) while downgrading Quest Diagnostics (NYSE:DGX), citing valuation-related arguments as the main reasons for the rating ...

Principal Financial Group Inc. grew its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 0.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 95,004 ...

Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and trades.